Navigation Links
Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials
Date:9/25/2008

HREF="http://studio-5.financialcontent.com/prnews?Page=Quote&Ticker=NTII" onClick="var s=s_gi(s_account); var hd1 = document.getElementById('headline'); s.tl(this,'o',getLinkName('Company Sanpshot'));" >NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug in Phase 3 trials for brain swelling.

NOTE: Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including uncertainties regarding the development of Viprinex for acute ischemic stroke, delays or other problems with our clinical trials, the outcome of the interim analysis, the time and costs for obtaining approval for Viprinex, and levels of future expenditures and capital resources needed to fund operations, as well as other risks detailed from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K, as updated periodically in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release and we undertake no obligati
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  Synapse Biomedical Inc. ( www.synapsebiomedical.com ) announced ... post-approval study of its NeuRx DPS® System for ... the FDA enrollment requirement was implanted over a ... NeuRx DPS®, which is the only medical device ... is a humanitarian device that obtained approval at ...
(Date:9/30/2014)... , Sept. 30, 2014 EXECUTIVE SUMMARY ... Industry Outlook to 2017 - Increasing Demand from ... analysis of the industry past, present and future ... Canada market with outlook to ... dietary supplements. Additionally the sub-segments of the industry, ...
(Date:9/30/2014)... DURHAM, N.C. , Sept. 30, 2014 /PRNewswire/ ... that Viztek LLC (Viztek), a leading provider of ... licensed HeartIT,s zero footprint patent portfolio. The licensed ... to provide access to diagnostic-quality medical images in ... part of the agreement, Viztek and its Subsidiaries ...
Breaking Medicine Technology:Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 3North America Nutraceuticals Industry Outlook to 2017- Increasing Demand from Ageing Population to Drive Growth 2North America Nutraceuticals Industry Outlook to 2017- Increasing Demand from Ageing Population to Drive Growth 3
... 2011 Varian Medical Systems (NYSE: ... order from U.S. Customs and Border Protection (CBP) for multiple ... represents the company,s largest single order for Varian,s IntellX gantry ... border, scanning vehicles for both border security and manifest verification ...
... PITTSBURGH, Jan. 27, 2011 Mylan Inc. (Nasdaq: ... subsidiary Matrix Laboratories Limited has signed an agreement ... manufacture, market and distribute a generic version of ... pending its regulatory approval for the treatment of ...
Cached Medicine Technology:Varian Medical Systems' Security and Inspection Products Group Receives Largest Single Order for IntellX Systems 2Mylan's Matrix Obtains License for Promising HIV/AIDS Treatment 2
(Date:9/30/2014)... HealthDay Reporter , MONDAY, Sept. ... broad-spectrum antibiotics before the age of 2 may face ... new research suggests. Broad-spectrum antibiotics target a larger ... study. "It is a reason to think about ... picking," said lead researcher Dr. Charles Bailey, attending physician ...
(Date:9/30/2014)... Edward D. Buckingham, M.D., owner of ... approved to be a director of a fellowship for ... (AAFPRS) fellowship program. The announcement came last week from ... The Educational and Research Foundation for the AAFPRS fellowship ... the finest postgraduate program in the world for the ...
(Date:9/30/2014)... Gummy teeth treatment expert, Dr. ... dark gums. Dark gums are usually considered a cosmetic ... about their smiles. Dr. Farnoosh has pioneered a procedure ... of the few dental professionals nationwide offering black ... leaders, high-ranking officials and patients from all over the ...
(Date:9/30/2014)... HealthDay Reporter TUESDAY, Sept. ... supplements won,t prevent the return of a common type of ... In fact, 64.1 percent of those taking fish oil for ... over the course of 16 months, compared to 63.2 ... did not reduce the twin ills of inflammation or oxidative ...
(Date:9/30/2014)... 30, 2014 Lea Blackwell, M.D., a ... cancer patients a new, more practical and comfortable option ... undergo mastectomies, biopsies and lumpectomy surgeries use special bras ... after seeing her patients describe the bra as scratchy, ... a new bra in her spare time. , ...
Breaking Medicine News(10 mins):Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 2Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 3Health News:Dr. Edward Buckingham Approved to be Fellowship Director for Facial Plastic Surgery 2Health News:Dr. Edward Buckingham Approved to be Fellowship Director for Facial Plastic Surgery 3Health News:Gummy Smile Dentist, Dr. Alex Farnoosh, is Now Offering Gum Depigmentation for Dark Gums 2Health News:Fish Oil Supplements Have Little Effect on Irregular Heartbeat: Study 2Health News:Fish Oil Supplements Have Little Effect on Irregular Heartbeat: Study 3Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 2Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 3
... many as 10% of people of Asian descent, operations ... mathematical models that verified the cost effectiveness of hepatitis ... vaccinate millions of Asian and Pacific Islander adults in ... to a paper in a journal of the Institute ...
... (HealthDay News) -- In the days after they start ... bupropion or venlafaxine, nursing home residents are at significantly ... Researchers found the increased risk for falls also ... their current prescription. "Our results identify the days ...
... increasing globally. Requiring two doctors to agree that a ... baby, rather than just needing one opinion, providing internal ... and seeking support from local opinion leaders may reduce ... relaxation classes for women with a fear or anxiety ...
... spoils of war for returning veterans may include addictions, ... witnessed. Now a University of Houston joint study ... Development service looks to address these issues through the ... College of Social Work (GCSW) joins Baylor College of ...
... News) -- Depression rates are higher in richer countries ... who compared socioeconomic conditions with depression. About 121 ... quality of life by affecting their ability to ... suicide and causes 850,000 deaths every year. Detailed ...
... 26 (HealthDay News) -- A person,s brain works hard to ... people,s shoes, no matter how different they may be, a ... California found people automatically attempt to empathize -- even with ... people must use two separate regions of their brain. ...
Cached Medicine News:Health News:INFORMS study: OR models of hepatitis B prove decisive in treating millions in US, China 2Health News:INFORMS study: OR models of hepatitis B prove decisive in treating millions in US, China 3Health News:Certain Antidepressants Linked to Falls in Nursing Homes 2Health News:Local efforts can stem the increasing unnecessary cesarean sections 2Health News:Returning vets' alcohol abuse addressed in virtual reality study 2Health News:Depression Higher in Wealthier Nations 2Health News:Human Brains Wired to Empathize, Study Finds 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: